Rahul Rao is a freelance science writer, graduate of New York University’s Science, Health and Environmental Reporting Program, and “Doctor Who” fan.
Rahul Rao
From this contributor
Web app tracks pupil size in people, mice
The app relies on artificial intelligence and could help researchers standardize studies of pupil differences in autistic people and in mouse models of autism.
New library catalogs the human gut microbiome
Researchers put hundreds of gut bacteria strains through their paces to chart the compounds each creates — and to help others explore the flora's potential contribution to autism.
New unified toolbox traces, analyzes neurons
‘SNT’ helps researchers sift through microscope images to reconstruct and analyze neurons and their connections.
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.